Abstracts tagged "Psoriatic arthritis"

Abstract Number: 108 • 2012 ACR/ARHP Annual Meeting
Disparity Between Sonographic and Clinical Criteria of Remission in Psoriasis Arthritis
Christian Dejaco¹, Rusmir Husic², Judith Gretler³, Winfried B. Graninger⁴ and Josef Hermann², ¹Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom, ²Rheumatology, Medical University Graz, Graz, Austria, ³Med Univ Klinik Graz, Auenbruggerplatz 15, Graz, Austria, ⁴Internal medicine/Rheumatology and Immunology, Medical University Graz, Graz, Austria
Background/Purpose: To compare ultrasound and clinical definitions of remission in psoriasis arthritis (PsA). Methods: Prospective study of 70 consecutive PsA patients [mean age 51.1 (±SD…
Abstract Number: 2228 • 2012 ACR/ARHP Annual Meeting
The Caspar Classification Criteria and Response to TNF Blockade in Rheumatologists Practice: A Large Observational Cohort Study
Burkhard Moller¹, Almut Scherer², J. Dudler³, Bettina Weiss⁴, Nikhil Yawalkar⁵ and Peter M. Villiger⁶, ¹Rheumatology, Inselspital University Hospital, Bern, Switzerland, ²SCQM Foundation, Zurich, Switzerland, ³Rheumatology, Cantonal Hospital Fribourg, Fribourg, Switzerland, ⁴Division of Rheumatology, Balgrist University Hospital, Zurich, Switzerland, ⁵Dermatology, MD, Bern, Switzerland, ⁶Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland
The CASPAR classification criteria and response to TNF blockade in Rheumatologists' practice: A large observational cohort study Burkhard Möller, Almut Scherer, Jean Dudler, Bettina Weiss,…
Abstract Number: 114 • 2012 ACR/ARHP Annual Meeting
US Examination of Wrists and Hands: A Comparison Between Rheumatoid Arthritis and Psoriatic Arthritis
Andrea Delle Sedie¹, Elisa Cioffi¹, Linda Carli², Elena Sardano³, Stefano Bombardieri¹ and Lucrezia Riente¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ³Immunology Unit, University of Pisa, Immunology Unit, University of Pisa, Italy
Background/Purpose: very little is known about the differences in joint and periarticular structure involvement in rheumatoid or psoriatic arthritis (PsA). The main pathological features detected…
Abstract Number: 2058 • 2012 ACR/ARHP Annual Meeting
Differences in Psychological Characteristics Between Patients with Rheumatoid and Psoriatic Arthritis
Panagiota Tsitsi¹, Athina Theodoridou¹, Foteini Lada¹, Konstantinos Papanikolaou², Despina Dimopoulou¹, Georgios Garyfallos³, Alexios Benos⁴ and Alexandros Garyfallos⁵, ¹4th Department of Internal Medicine,Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece, ²Psychiatric Hospital of Petra Olympus, Katerini, Greece, Katerini, Greece, ³2nd Department of Psychiatry, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece, ⁴Department of Hygiene, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece, ⁵4th Department of Internal Medicine, Aristotle University, Hippocratio Hospital, 4th Department of Internal Medicine, Aristotle University, Hippocratio Hospital, Thessaloniki, Greece
Background/Purpose: Both rheumatoid (RA) and psoriatic arthritis (PsA) seem to have a negative impact on patients’ psychological status mostly due to the chronic character of…
Abstract Number: L13 • 2012 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of a Phase 3, Randomized, Controlled Trial
Arthur Kavanaugh¹, Philip J. Mease², Juan J. Gomez-Reino³, Adebajo Adewale⁴, Jürgen Wollenhaupt⁵, ChiaChi Hu⁶ and Randall Stevens⁶, ¹UCSD School of Medicine, La Jolla, CA, ²Rheumatology Research, Swedish Medical Center, Seattle, WA, ³Rheumatology, Hospital Clinico Universitario, Santiago, Spain, ⁴University of Sheffield, Sheffield, United Kingdom, ⁵Schön Klinik Hamburg Eilbek, Hamburg, Germany, ⁶Celgene Corporation, Warren, NJ
Background/Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate a network of pro- and anti-inflammatory mediators, including those implicated in the etiopathogenesis of…
Abstract Number: 1369 • 2012 ACR/ARHP Annual Meeting
Severe Joint Damage in Psoriatic Arthritis: Mutilans and Ankylosis
Amir Haddad¹, Arane Thavaneswaran¹, Dafna D. Gladman² and Vinod Chandran³, ¹Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Patients with Psoriatic arthritis (PsA) who develop severe joint damage have severe functional disability and increased mortality risk. The most severe form of PsA…
Abstract Number: 1371 • 2012 ACR/ARHP Annual Meeting
Predictors of Erosion-Free Psoriatic Arthritis
Zahi Touma¹, Arane Thavaneswaran², Vinod Chandran³ and D. D. Gladman⁴, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: A number of patients with psoriatic arthritis (PsA) remain erosion-free despite years of disease. We aimed to determine the prevalence, characteristics and predictors of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].